Evidence map›Paper›PMID 41706499›Full record

SynthesisAnnals of medicine2026

Acute leukemia during pregnancy: a single center experience with 23 cases, 2012-2022 and literature review.

Wei Liu, Jiamin Guo, Dongzheng Gai, Kai-Xuan Zhang, Yi Liu, Xie-Lan Zhao, Xiao Fu, Steven T Rosen, Cong Chen, Fangping Chen

Abstract readReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wei LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0001-9466-7452
Jiamin GuoIrell & Manella Graduate School of Biological Sciences, Beckman Research Institute, City of Hope, Duarte, CA, USA.
Dongzheng GaiHeping Hospital Affiliated to Changzhi Medical College, Changzhi, China.
Kai-Xuan ZhangDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yi LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xie-Lan ZhaoDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiao FuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Steven T RosenDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Cong ChenDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Fangping ChenDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveAcute Leukemia (AL) diagnosed during pregnancy is uncommon, and the management of AL complicated by pregnancy is a poorly studied area that faces a therapeutic dilemma.

method23 cases diagnosed with AL during pregnancy were collected from our center between 2012 and 2022. Additionally, we summarized 17 clinical studies on AL diagnosed during pregnancy.

resultSixteen AML and seven ALL patients were diagnosed during pregnancy in our center; most patients diagnosed during the first or second trimester tended to receive chemotherapy after abortion. All patients diagnosed during the third trimester opted to defer therapy until after delivery. The rate of overall response rate (ORR) was 77.3%, which was found to be similar to that of the general population. A Short delay in initiating anti-leukemia treatment is not associated with a negative impact on prognosis. We conducted a meta-analysis of the literature, and the summary relative complete remission (CR) rate was 76.9% (95%CI 69.1-84.6%) (Random Effects Model I^2 = 66%,

conclusionOur findings suggest that for non-M3 AL patients can sometimes be managed during pregnancy. For M3 patients, early treatment potentially yield favorable outcomes for both the mother and fetus, using ATRA-based regimens without arsenic trioxide (in the second and third trimester) or standard chemotherapy (in the second trimester) may be considered a treatment option.

Indexed as

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaPregnancy Complications, NeoplasticAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansPregnancyPrognosisRemission InductionYoung AdultAntineoplastic Agentsacute leukemiadeliverymaternal and fetal outcomePregnancy

Identifiers

PMID41706499
PMCPMC12918274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.